

H1500.H15B Lot No. 789

Cryopreserved Human Hepatocytes

Donor Information

 Demographics
 Serology

 Gender:
 Female
 CMV: (-)

 Age:
 59 Years
 HIV: (-)

 Race:
 Caucasian
 HBV: (-)

 Cause of Death:
 Cerebrovascular Accident
 HCV: (-)

Assured Minimum Yield: 4.0 x 10⁶ per vial

Viability: 83.1%

(Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and Hepatocyte Isolation Kit.)

Enzyme	Marker substrate reaction (pmol/cells per inc/min)	
CYP1A2	Phenacetin O-dealkylation	63.9 ± 5.7
CYP2A6	Coumarin 7-hydroxylation	7.17 ± 0.86
CYP2B6	Bupropion hydroxylation	10.6 ± 0.5
CYP2C8	Amodiaquine N-dealkylation	143 ± 13
CYP2C9	Diclofenac 4'-hydroxylation	76.5 ± 6.8
CYP2C19	S-Mephenytoin 4'-hydroxylation	1.21 ± 0.18
CYP2D6	Dextromethorphan O-demethylation	35.6 ± 6.2
CYP2E1	Chlorzoxazone 6-hydroxylation	289 ± 30
CYP3A4/5	Testosterone 6β-hydroxylation	217 ± 26
CYP3A4/5	Midazolam 1'-hydroxylation	20.7 ± 0.5
CYP4A11	Lauric acid 12-hydroxylation	62.2 ± 11.8

CAUTION: These hepatocyte samples are from donors who tested negative for HIV and hepatitis. However, we recommend that these samples be considered as potential biohazards and that universal precautions be used when working with human derived products.

Store vials in liquid nitrogen, vapor phase.



Data sheet prepared 8/13/08